Tikun Olam Cannbit Pharmaceuticals Ltd. Logo

Tikun Olam Cannbit Pharmaceuticals Ltd.

A medical cannabis company pioneering research and pharma-grade production.

TKUN | TA

Overview

Corporate Details

ISIN(s):
IL0010843675
LEI:
Country:
Israel
Address:
Ha'arbaa Street 21, 6473921 Tel Aviv-Yafo

Description

Tikun Olam Cannbit Pharmaceuticals Ltd. is a medical cannabis company recognized as a pioneer in clinical research and the modern application of medical cannabis. The company grows and supplies a range of medical marijuana products manufactured in advanced EU-GMP certified facilities. Formed through the 2019 acquisition of Tikun Olam by Cannbit Pharmaceuticals, the entity combines extensive experience in patient care, having treated tens of thousands of individuals, with pharmaceutical-grade production capabilities. Its core mission is centered on developing and providing high-quality, standardized cannabis-based treatments for a variety of medical conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-04-24 14:21
Rights Offering and Identifying Details for New Security: TIKUN OLAM R5
Hebrew (modern) 182.1 KB
2022-08-17 17:30
Opening of Trading On August 18 2022-TIKUN OL CN W3
Hebrew (modern) 107.6 KB
2022-07-26 15:47
Rights Offering and Identifying Details for New Securities-Correction
Hebrew (modern) 185.9 KB
2022-07-26 15:04
Rights Offering and Identifying Details for New Securities-TIKUN OL CAN R4, TIK…
Hebrew (modern) 314.1 KB
2021-05-30 18:08
Tikun Olam-Cannbit – Rights Offering and Identifying Details for New Security
Hebrew (modern) 430.0 KB
2020-10-14 14:50
Tikun Olam Canb – Rights Offering and Identifying Details for New Security
Hebrew (modern) 431.2 KB

Automate Your Workflow. Get a real-time feed of all Tikun Olam Cannbit Pharmaceuticals Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tikun Olam Cannbit Pharmaceuticals Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tikun Olam Cannbit Pharmaceuticals Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.